Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A good day to accumulate
Yawn
Nothing new here, move along.
He had a go at that yesterday and was ignored...
Valuein,
"CEOs historical confident statements" are just that . . . historical. This is a new phase. We are forward looking.
Dredging up and manipulating old 'opinions' like that is just a weedy, underhand way to FUD spam. We tend not to tolerate much of that on this BB.
As I've said before, in my view, the sp not responding to what one can positively infer re AVA6K is broken trust in CEOs historical confident statements re. LFT. Investors wondering if AVA6K could be LFT scenarios playing out re. confidence. Hopefully AVA6K results will help build back trust in CEO confidence statements.
I stand corrected spbhoy, I forgot he posted twice, so yes odd that only certain posts were removed
Very true @vegas22, but he also mentioned 60p in the other thread at 00:26...when he exposed himself (as sam smith @clonlow on Twitter). LOL.
https://twitter.com/clonlow/status/1544827764724961280?s=20&t=ogONik5qyMxihylluDLGuw
I've been reporting too, just a correction it was a different thread ....
£1 or £1.20 the whole thread has been removed
This time however, I've started asking LSE why he's still has an account - and will continue to do so henceforth as long as he does.
Me too.
I've been reporting all his posts so does make sense
It makes no sense. He’s got multiple IDs. Is running a pump and dump and then a short and distort but still has an LSE account. How hasn’t he been banned?
Interesting to see that Wressmycash posts on this thread and also those from MrRiipley and others which referred to his Tweets as @clonlow, have all been removed. Surely a little odd, given that there was nothing offensive therein, but simply Wressmycash making a clown of himself
Perhaps the market also knows, or at the very least is respecting the potential based on what we know / assume right now.
At the current GBP 260 million MC, there is some value being assigned. Clearly, when solid data is released proving the platform, the potential becomes real and x10 on the current MC looks very cheap.
Top post Energy, they know ,
‘It works.’
Good post...
I agree with all of the above. But this information has not (yet) translated into the SP and so it presents a great buying opportunity. I have maxed out and now waiting very patiently for the first big inflexion points in September/Q3 2022... which is not that too long away. I think over the next two years, there will be multiple inflexions .. I am looking forward to it.
Avacta BOD’s must be sitting on 4 Aces or a royal flush and know there is an almighty pot for the taking
There can’t be another company on AIM with a BOD and senior management team with this much quality.
They only have about £25 million left in the bank but they are keeping this top team motivated.
They keep adding top talent
Avacta then moves a whole division to a new HQ in London. (Is a move of just 60 miles prudent with their cash flow and ongoing clinical trial costs.)
50% of the following team were added after AVA6000 trial started.
They have recruited some of the worlds most renowned oncology talent, do you think they would still be around if this trial wasn’t showing very positive results so far.
Remember if precision fails Avacta would be relying on Affimers to target cancer, which would be years away.
This team would start to leave this company.
Avacta couldn’t afford to keep them until affimers come through.
But what is happening they continue to recruit even IP lawyers.Plus all the clues.
Aug 21.Trial starts 1st patient dosed with AVA6000.
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer.
SDMC meets twice trial continues.
Sep 21.The three new members of the SAB are Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD, and Dr Ste´phane Champiat MD, PhD.SDMC meets twice trial continues.
Nov 21.FDA Approval of its Investigational New Drug (IND) Application for AVA6000.SDMC meets twice trial continues.
Jan 22.Avacta Selects Second pre|CISIONTM Pro-drug Candidate.SDMC meets twice trial continues.
Feb 22.Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin.
AS and Fiona McLaughlin announce remarkable consistent data and that biopsies will be performed even though they are not needed for this part of trial.
Mar 22.Top American Oncologist Christina Coughlin joins Avacta board.Avacta sells Animal health division.
April 22.Avacta presents preclinical data on AVA6000 at AAC
Glasgow starts recruiting with Sheffield and Newcastle and USA also getting ready to recruit patients.
May 22.Avacta establishes new Therapeutics headquarters at Scale Space,White City London
Jupiter starts to reduce their short.
June 22.SDMC meets twice trial continues.
Avacta Announces Dose Escalation 2.
AVACTA BOD.
Alastair Smith. Chief Executive Officer.
Tony Gardiner. Chief Financial Officer.
Eliot Forster. Non Executive Chairman.
Trevor Nicholls. Non Executive
Paul Fry. Non Executive
Mark A. Goldberg, MD.
Christina Coughlin. Non Executive Director.
Avacta Senior Team.
Neil Bell
Chief Development Officer, Therapeutics
Dr. Mike Owen
Scientific Advisory Board
Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD,
Dr Ste´phane Champiat MD, PhD.
Fiona McLaughlin
Chief Scientific Officer
Diagnostics DIvision
David Wilson
Commercial Director,
Matt Johnson
Chief Scientific Officer,
Marc Green Development
Gemma WilsonHeadQA/RA
Adrian Ruskin Ops director
Avacta BOD’s must be sitting on 4 Aces or a royal flush and kno